EEG Changes in Pediatrics With Language Dysfunction Evaluation of Sleep EEG Changes in Paediatric Patients With Language Dysfunction: A Follow up Study. EEG Changes in Pediatrics With Language Dysfunction

Evaluation of Sleep EEG Changes in Paediatric Patients With Language Dysfunction: A Follow up Study. Evaluation of Sleep EEG Changes in Paediatric Patients With Language Dysfunction: A Follow up Study. Evaluation of Sleep EEG Changes in Pediatric Patients With Language Dysfunction : A Follow up Study

In general, the severity of the patients' language disorders fluctuated with the degree of EEG epileptiform activity . Since then, a spectrum of disorders, often referred to collectively as the epilepsy-aphasia spectrum, have been described that share features of sleep potentiated EEG abnormalities, cognitive problems, and rare or even absent clinical seizures .

In our study , Investigators evaluated the sleep EEG changes in pediatrics with languague dysfunction then in patients with EEG changes , investigators gave treatment according to type of EEG changes and investigators did a follow up assessment of language , EEG changes and frequency of clinical seizures if present at first .

Study Overview

• Status: Completed
• Conditions: Language Disorders in Children
• Intervention / Treatment: Drug: Methylprednisolone and or prednisolone

Detailed Description

Language dysfunction is one of the most common problems in paediatrics. There is increased interest in association of epilepsy and epileptiform EEG abnormalities to language dysfunction.

Electrographic status epilepticus in sleep or continuous spike - wave in slow wave during sleep, is a typical feature of acquired epileptic aphasia feature in sleep, or continuous spike-wave in slow-wave sleep, is a typical.

Our study screened for sleep potentiated epileptiform discharges in children with language dysfunction and effect of treatment of these epileptiform discharges on language dysfunction improvement.

The aim of our work :

• The primary aim of this work was to screen for sleep potentiated epileptiform discharges in children with language dysfunction.
• To evaluate effect of treatment of these epileptiform discharges on Language dysfunction improvement .

Patients and methods :

• Type of Study: Observational longitudinal study.
• Study Period: From February 2020 till November 2021 .
• Study Population: Patients was recruited from the Pediatric Neurology Clinic, Pediatric Outpatient Clinic, Phoniatrics Outpatient Clinic and the Inpatient Neurology ward at the Ain Shams University Children hospital, Cairo, Egypt.

• Inclusion Criteria: The study was conducted on Children with :

  • Language delay (their language age is below their chronological age ),or Language regression (any convincing report of loss of previously acquired language skills, whether or not prior language development was reported as normal or delayed) (Meilleur et al., 2009)
  • Age from 3 to 10 years old.

• Exclusion Criteria:

  • Patients with hearing problems.
  • Patients whose language delay can be explained by organic disease (e.g. post Hypoxic ischemic encephalopathy, known inborn error of metabolism - whether this language delay is isolated or occurring in the context of global developmental delay).
  • Patients with mental delay.
  • Patients with autism spectrum disorder ( according to DSM-5 standardized criteria, 2013)
  • Enviromentally deprived patients.
• Sampling Method: Consecutive random sampling .
• Sample Size: 93 patients with delayed or regressed language development. (Using PASS 11 program for sample size calculation and according to Nasr et al. (2001), the expected frequency of children with epileptiform discharges =15-60%, assuming that frequency in study population =40%±10%, sample size of 93 children can detect this frequency at 95% confidence level).
• Ethical Considerations: A written informed consent was taken from the parents or legal guardians before enrolment, after fully explaining to them the nature of the study.

The approval of the Research Ethics Committee at Ain Shams University was obtained ( M.D 4312020 ) .

• Study Procedures:

  1. Full history taking:

     • Detailed developmental history.
     • Family history of same condition.
     • History of seizures.

  2. Clinical examination including:

     • General examination.
     • Full neurological examination.
     • Vocal tract examination.

  3. Clinical diagnostic aids :

     • IQ assessment by rapid screening test of Stanford Binet 5th version (Hanoura, 2002).
     • Assessment of language age by modified pre-school language screening test - the Arabic version (Abou-Hassiba, 2011).

  4. Investigations:

     • MRI of the brain will be done. ((1.5 T) Phillips Achieva and Inginea )
     • Auditory brainstem response (ABR). (GSI Audera will be used for acquiring ABR waveforms).
     • 90 minutes sleep EEG (one full sleep cycle) (using Nicolet REF 515-019000 rev 06, CareFusion, Middletown, WI 53562, USA) and placing electrodes by 10-20 placement system.

     Patients whose EEG showed epileptogenic activity ,received treatment and a follow up EEG and Assessment of language age by modified pre-school language screening test - the Arabic version will be done after 6 months.

• Statistical Analysis: Numerical data will be summarized using mean and standard deviations or medians and inter quartile ranges. Qualitative data will be presented as count and percentage, p-value <0.005 will be considered significant.
• Statistical Package: Statistical analysis will be performed with statistical package for social science (SPSS)version 23.0 (SPSS Inc., Chicago, Illinois, USA).

• Study Type: Interventional
• Enrollment (Actual): 93
• Phase: Phase 3

Contacts and Locations

Study Locations

• Egypt
  • Cairo, Egypt, 02
    • Omnia Alaa Mahsoub

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years to 10 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• o Language delay (their language age is below their chronological age ),or Language regression (any convincing report of loss of previously acquired language skills, whether or not prior language development was reported as normal or delayed) (Meilleur et al., 2009)

  • Age from 3 to 10 years old.

Exclusion Criteria:

• o Patients with hearing problems.

  • Patients whose language delay can be explained by organic disease (e.g. post Hypoxic ischemic encephalopathy, known inborn error of metabolism - whether this language delay is isolated or occurring in the context of global developmental delay).
  • Patients with mental delay.
  • Patients with autism spectrum disorder ( according to DSM-5 standardized criteria, 2013)
  • Enviromentally deprived patients.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Patients without EEG changes or clinical seizures
Experimental: Patients with EEG changes or clinical seizures	Drug: Methylprednisolone and or prednisolone; we gave methylprednisolone and or prednisolone to patients with EEG activity and follow up the effect of the drug on language

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
language age of the patient	we follow up language age of the patient after treatment	6 months

Collaborators and Investigators

• Sponsor: Ain Shams University

Study record dates

Study Major Dates

• Study Start (Actual): February 20, 2020
• Primary Completion (Actual): November 10, 2021
• Study Completion (Actual): May 10, 2022

Study Registration Dates

• First Submitted: August 1, 2022
• First Submitted That Met QC Criteria: August 2, 2022
• First Posted (Actual): August 4, 2022

Study Record Updates

• Last Update Posted (Actual): August 4, 2022
• Last Update Submitted That Met QC Criteria: August 2, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Communication Disorders; Language Disorders; Physiological Effects of Drugs; Autonomic Agents; Peripheral Nervous System Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Neuroprotective Agents; Protective Agents; Prednisolone; Methylprednisolone Acetate; Methylprednisolone; Methylprednisolone Hemisuccinate; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate
• Other Study ID Numbers: M.D4312020

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes